GSK’s chief executive, Luke Miels, laid out a three-year plan on July 28, 2026, to make the U.K. pharmaceutical group faster and more agile, with a major focus on expanding the company’s late-stage drug development. The company intends to generate £1.9 billion in annual savings by 2029 and will reinvest much of those savings to advance its late-stage pipeline.
Miels, who took the top job about six months ago, also announced that GSK now plans to start at least 20 Phase 3 trials this year — double the number the company had disclosed at the start of 2026.
Miels framed these moves as part of an effort to make GSK more agile and to build a portfolio of potential best-in-class products across its core therapy areas.
Miels named several areas that will be priorities for the company’s renewed investment in late-stage research. Those include long-standing company strengths such as vaccines and HIV, as well as newer focuses like oncology and liver disease. The company has been moving into some of these newer target areas in recent months.
According to Miels, the strategy is meant to position GSK for sustained growth by concentrating resources on later-stage programs with clearer commercial potential. The plan combines cost savings with a stepped-up clinical trial schedule, reflecting a shift toward deploying more capital into Phase 3 development.
Miels emphasized building "a set of potential best-in-class products across our core therapy areas," signaling a mix of safeguarding established franchises while expanding into additional disease areas.
The company did not disclose how many roles might be affected by the savings drive. In response to questions about workforce impact, Miels declined to provide a figure. Other operational and program-level details beyond the headline savings target and the Phase 3 trial count were not reported in the source.
Miels took the helm roughly six months before the July 28 announcement. The moves described reflect a common industry pattern: combining internal cost reductions with increased late-stage trial activity to try to drive revenue growth in future years. GSK’s existing strengths in vaccines and HIV remain central to the plan, while the company is also committing resources to grow in oncology and liver disease.
The source notes that GSK had already disclosed plans for 10 Phase 3 trials earlier in 2026; the newly stated goal of at least 20 Phase 3 starts signals a materially more aggressive clinical schedule for the year.
This coverage is based on a STAT+ exclusive report by Andrew Joseph published July 28, 2026. The article summarized the announcements from GSK’s CEO but noted that certain operational specifics, including the number of jobs affected and program-level details, were not disclosed in the source material.
For investors, the combination of large-scale cost savings and a stepped-up Phase 3 program changes the company’s near-term spending profile and could shift its medium-term revenue outlook depending on trial outcomes. For patients and clinicians, more Phase 3 trials mean a faster path to potential new therapies in the disease areas GSK highlighted, but outcomes and timelines will depend on the specifics of those individual programs, which were not reported in the source.
The plan was announced publicly by GSK’s CEO about six months after he assumed the role. The announcement is part of a broader effort to reposition the company’s resource allocation toward programs nearer to potential market approval while trimming costs elsewhere. Further details on the execution of the strategy will need to come from GSK as the company rolls out the program and identifies the Phase 3 studies it will start.
(Reporting by Andrew Joseph for STAT; the full STAT+ article is behind a subscriber wall. This rewrite uses only facts and figures reported in that source.)
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.